Tech Company Financing Transactions
Deciphera Pharmaceuticals Funding Round
On 9/21/2015, Deciphera Pharmaceuticals landed $75 million in Series B financing from New Leaf Venture Partners and private investors.
Transaction Overview
Company Name
Announced On
9/21/2015
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series B
Investors
New Leaf Venture Partners (Lead Investor) (Liam Ratcliffe)
Proceeds Purpose
The proceeds will enable Deciphera to advance its pipeline of proprietary switch control kinase inhibitors through multiple key clinical milestones.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
200 Smith St.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Deciphera Pharmaceuticals (NASDAQ: DCPH) was established in 2003 as a drug discovery and development company with the mission to design, optimize and introduce best-in-class small molecule switch inhibitors of protein kinases for human clinical trials and the global pharmaceutical marketplace through the use of its proprietary drug discovery technology platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steven Hoerter
Chief Financial Officer
Tucker Kelly
Chief Scientific Officer
Daniel Flynn
VP - General Counsel
Jeffrey Held
VP - Human Resources
Peter Lasky
Browse more venture capital transactions:
Prev: 9/21/2015: SPORTalk venture capital transaction
Next: 9/21/2015: Cruise venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs